<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37093032</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2151-4658</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Arthritis care &amp; research</Title><ISOAbbreviation>Arthritis Care Res (Hoboken)</ISOAbbreviation></Journal><ArticleTitle>Triphasic: Preeclampsia, Systemic Lupus Erythematosus, and Severe Neutropenia With Use of Granulocyte Colony Stimulating Factor in the Partum and Postpartum Period.</ArticleTitle><Pagination><StartPage>2036</StartPage><EndPage>2043</EndPage><MedlinePgn>2036-2043</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acr.25138</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Donohue</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1807-6284</Identifier><AffiliationInfo><Affiliation>University of Wisconsin, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez</LastName><ForeName>Shelby</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Wisconsin, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Tripti</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of Wisconsin, Madison.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garg</LastName><ForeName>Shivani</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7272-2692</Identifier><AffiliationInfo><Affiliation>University of Wisconsin, Madison.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arthritis Care Res (Hoboken)</MedlineTA><NlmUniqueID>101518086</NlmUniqueID><ISSNLinking>2151-464X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>143011-72-7</RegistryNumber><NameOfSubstance UI="D016179">Granulocyte Colony-Stimulating Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011225" MajorTopicYN="Y">Pre-Eclampsia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009503" MajorTopicYN="Y">Neutropenia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016179" MajorTopicYN="N">Granulocyte Colony-Stimulating Factor</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049590" MajorTopicYN="N">Postpartum Period</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>26</Day><Hour>13</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>24</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>24</Day><Hour>10</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37093032</ArticleId><ArticleId IdType="doi">10.1002/acr.25138</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol 2020;135:e237-60.</Citation></Reference><Reference><Citation>Bouma W, Klinkenberg TJ, van der Horst IC, et al. Mitral valve surgery for mitral regurgitation caused by Libman-Sacks endocarditis: a report of four cases and a systematic review of the literature. J Cardiothorac Surg 2010;5:13.</Citation></Reference><Reference><Citation>Smyth A, Oliveira GH, Lahr BD, et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010;5:2060-8.</Citation></Reference><Reference><Citation>Garg S, Singh T, Panzer SE, et al. Multidisciplinary lupus nephritis clinic reduces time to renal biopsy and improves care quality. ACR Open Rheumatol 2022;4:581-6.</Citation></Reference><Reference><Citation>Clowse ME, Jamison M, Myers E, et al. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 2008;199:127.e1-6.</Citation></Reference><Reference><Citation>Clowse ME, Magder LS, Witter F, et al. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005;52:514-21.</Citation></Reference><Reference><Citation>Clark CA, Spitzer KA, Nadler JN, et al. Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol 2003;30:2127-32.</Citation></Reference><Reference><Citation>Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000;15:145-51.</Citation></Reference><Reference><Citation>&#xdc;nl&#xfc; O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol 2016;3:75-84.</Citation></Reference><Reference><Citation>Petri M. Antiphospholipid syndrome [review]. Transl Res 2020;225:70-81.</Citation></Reference><Reference><Citation>Petri M. Pregnancy and systemic lupus erythematosus [review]. Best Pract Res Clin Obstet Gynaecol 2020;64:24-30.</Citation></Reference><Reference><Citation>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 2020;72:529-56.</Citation></Reference><Reference><Citation>Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012;64:2311-8.</Citation></Reference><Reference><Citation>Yelnik CM, Laskin CA, Porter TF, et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med 2016;3:e000131.</Citation></Reference><Reference><Citation>Liu X, Qiu Y, Yu ED, et al. Comparison of therapeutic interventions for recurrent pregnancy loss in association with antiphospholipid syndrome: a systematic review and network meta-analysis. Am J Reprod Immunol 2020;83:e13219.</Citation></Reference><Reference><Citation>Duley L, Meher S, Hunter KE, et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2019;2019:CD004659.</Citation></Reference><Reference><Citation>Germain S, Nelson-Piercy C. Lupus nephritis and renal disease in pregnancy. Lupus 2006;15:148-155.</Citation></Reference><Reference><Citation>Chakravarty EF, Colon I, Langen ES, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol 2005;192:1897-904.</Citation></Reference><Reference><Citation>Baer AN, Witter FR, Petri M. Lupus and pregnancy [review]. Obstet Gynecol Surv 2011;66:639-53.</Citation></Reference><Reference><Citation>Sudjai D, Satho P. Relationship between maternal serum uric acid level and preeclampsia with or without severe features. J Obstet Gynaecol 2022;42:2704-8.</Citation></Reference><Reference><Citation>Sanchez-Ramos L, Sandroni S, Andres FJ, et al. Calcium excretion in preeclampsia. Obstet Gynecol 1991;77:510-3.</Citation></Reference><Reference><Citation>Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012;64:797-808.</Citation></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020;79:713-23.</Citation></Reference><Reference><Citation>Farrington CA. Kidney imaging and biopsy in pregnancy [review]. Adv Chronic Kidney Dis 2020;27:525-30.</Citation></Reference><Reference><Citation>Chen TK, Gelber AC, Witter FR, et al. Renal biopsy in the management of lupus nephritis during pregnancy. Lupus 2015;24:147-54.</Citation></Reference><Reference><Citation>Vasiliu IM, Petri MA, Baer AN. Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares. J Rheumatol 2006;33:1878-80.</Citation></Reference><Reference><Citation>Hellmich B, Schnabel A, Gross WL. Treatment of severe neutropenia due to Felty's syndrome or systemic lupus erythematosus with granulocyte colony-stimulating factor. Semin Arthritis Rheum 1999;29;82-99.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>